The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy

Annals of the Rheumatic Diseases

Volumn 67, Issue 2, 2008, Pages 182-188

  Van Der Heijde, Désirée ^f   Burmester, G ^a   Melo Gomes, J ^b   Codreanu, C ^c   Mola, E Martin ^d   Pedersen, R ^e   Freundlich, B ^e   Chang, D J ^e  

^a HUMBOLDT UNIVERSITY   (Germany)

^b SERVIMED   (Portugal)

^c Centrul de Boli Reumatismale   (Romania)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e PFIZER INC   (United States)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; METHOTREXATE;

ACCIDENTAL INJURY; ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANEURYSM; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BACTEREMIA; CARCINOMA; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; FEMALE; FEVER; HEADACHE; HEMATURIA; HERNIA; HIP FRACTURE; HUMAN; INFECTION; INFECTIOUS DIARRHEA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; REMISSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 38749088727     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.076166     Document Type: Article

References (29)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Akil M, Amos RS. ABC of rheumatology. Rheumatoid arthritis - I: Clinical features and diagnosis. BMJ 1995;310:587-90.
3. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts [comment]. Arthritis Rheum 2001;44:1234-6.
4. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854-60.
5. Pincus T, Callahan LF. The "side effects" of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 1993;32(Suppl 1):28-37.
6. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
7. Klaukka T, Kaarela K. Methotrexate is the leading DMARD in Finland. Ann Rheum Dis 2003;62:494; author reply 494-5.
8. Kremer JM. Methotrexate and emerging therapies. Rheum Dis Clin North Am 1998;24:651-8.
9. Kollias G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002;13:315-21.
10. Arend WP, Dayer JM. Inhibition of the production and effects of interieukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
11. Brennen FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
12. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
13. Weinblatt ME, Kremer JM, Bankhurst AO, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
14. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of Internal Medicine 1999;130:478-86.
15. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [comment] [erratum appears in N Engl J Med 2001 Jan 18;344:240]. N Engl J Med 2000;343:1586-93.
16. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
17. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
18. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group [comment]. N Engl J Med 2000;343:1594-602.
19. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis. Lancet 2004;363:675-81.
20. Klareskog L, van der Heijde D, Wajdula J, Pedersen R, Fatenejad S. Sustained efficacy and safety of etanercept and methotrexate, combined and alone, in RA patients: Year 3 TEMPO trial results [Abstract OP0009]. Ann Rheum Dis 2005;64(suppl III):59.
21. van der Heijde D, Klareskog L, Wajdula J, Pedersen R, Fatenejad S. Sustained halting of joint damage with combination etanercept and methotrexate: 3-year results from the TEMPO trial [Abstract SAT0194]. Ann Rheum Dis 2006;65(suppl II):509.
22. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
23. van der Heijde O, Klareskog L. Reply to letter by Yazici and Yazici commenting on the two-year report on the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2007;56:1031-2.
24. Strand V, Sharp JT. Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned? Arthritis Rheum 2003;48:21-34.
25. van Gestel A, van Riel P. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis: comment on the article by Felson et al. [comment]. Arthritis Rheum 1996;39:535-7.
26. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
27. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005;44:157-63.
28. van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006;65:1478-83.
29. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005;52:1009-19.